£495.00

The 2013-2018 Outlook for Irritable Bowel Syndrome (IBS) Therapeutics in the United States

Econometrics

Price data last checked 27 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 64 days · 64 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 64 days • 1 price levels

Days at Price

Price Analysis

Most common price: £495 (64 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 64 days

Description

This econometric study covers the latent demand outlook for irritable bowel syndrome (IBS) therapeutics across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,700 cities in the United States. For each city in question, the percent share the city is of it's state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-a-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for irritable bowel syndrome (IBS) therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the cities in the United States). This study gives, however, my estimates for the latent demand, or the P.I.E., for irritable bowel syndrome (IBS) therapeutics in the United States. It also shows how the P.I.E. is divided and concentrated across the cities and regional markets of the United States. For each state, I also show my estimates of how the P.I.E. grows over time. In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on strategic planning at graduate schools of business.

Product Specifications

Format: paperback
ASIN: B00E0VHF6C
Category: Books > Subjects > Business, Finance & Law > Economics > Econometrics
Domain: Amazon UK
Release Date: 17 July 2013
Listed Since: 23 July 2013

The 2013-2018 Outlook for Irritable Bowel Syndrome (IBS) Therapeutics in the United States

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2013 Report on Irritable Bowel Syndrome (IBS) Therapeutics: World Market Segmentation by City

The 2013-2018 Outlook for Inflammatory Bowel Disease Therapeutics in India

The 2013-2018 Outlook for Digestion Aids in India

Reclaim Your Life from IBS: A Scientifically Proven CBT Plan for Relief Without Restrictive Diets

The 2023-2028 Outlook for IBD (Ulcerative Colitis and Crohn's Disease) Treatments in China

The 2025-2030 World Outlook for IBD (Ulcerative Colitis and Crohn's Disease) Treatments

The 2013-2018 Outlook for Enterprise Service Bus (ESB) Technologies in The Americas

The 2013-2018 Outlook for Office Supplies, Stationery, and Gift Stores in India

The 2023 Report on IBD (Ulcerative Colitis and Crohn's Disease) Treatments: World Market Segmentation by City

The 2013-2018 Outlook for Enterprise Service Bus (ESB) Technologies in The Middle East

The 2023-2028 Outlook for Digestive Health Food and Drinks in the United States

The 2013-2018 Outlook for Women's Apparel and Accessories in India

The 2013-2018 Outlook for Non-Food Retailers in India

The 2013-2018 Outlook for Information Management (IM) Solutions and Services in India

The 2013-2018 Outlook for Enterprise Service Bus (ESB) Technologies in Asia

The 2013-2018 Outlook for Content Management Software in India

The 2013-2018 Outlook for E-Paper Displays in North America & the Caribbean

The 2013-2018 Outlook for Do-It-Yourself (DIY) and Home Improvement Products in India

The 2013-2018 Outlook for Women's Outerwear in India

The 2013-2018 Outlook for E-Learning Software in North America & the Caribbean

The 2013-2018 Outlook for Online Travel Services in the United States

The 2013-2018 Outlook for Software-As-A-Service (SaaS) Applications in The Middle East

The 2013-2018 Outlook for Herbal Digestion Aids in India

The 2013-2018 Outlook for Professional Service Automation (PSA) Software in North America & the Caribbean